Soros Fund Management’s Rapport Therapeutics RAPP Stock Holding History

Soros Fund Management’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,000	Closed	-$698K	–	234
2024 Q2	$698K	Buy	+30,000	New	+$695K	0.01%	174

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Soros Fund Management's RAPP Position: Q3 2024 in Review

Soros Fund Management sold out of Rapport Therapeutics (RAPP) in Q3 2024, closing a stake of 30,000 shares — an estimated $698K sold.

Soros Fund Management first reported a position in RAPP in Q2 2024 and held it in 1 quarter. The position peaked at $698K in Q2 2024. 55 funds tracked by Wall St. Rank hold RAPP as of Q3 2024.

Soros Fund Management reported no remaining Rapport Therapeutics position as of Q3 2024 after selling out during the quarter.
Soros Fund Management sold 30,000 Rapport Therapeutics shares in Q3 2024, an estimated $698K.
Soros Fund Management first reported a position in Rapport Therapeutics in Q2 2024 and held it in 1 quarter.
Soros Fund Management's Rapport Therapeutics position peaked at $698K in Q2 2024.
55 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2024.

Based on Soros Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.